Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)

Phase 4 Study of MR and APDT Vaccine

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01830257

Acronym

AEFI

Enrollment

1000

Registered

2013-04-12

Start date

2013-04-30

Completion date

2014-06-30

Last updated

2013-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Reaction to Drug

Brief summary

The investigators would remind the guardians of observation after immunization via sending short message and collect the information of AEFI by two ways, short message/telephone and website questionnaire.

Detailed description

The investigators will compare the rate between active and inactive surveillance of AEFI

Interventions

OTHERsending message

Sending the suggestive short message

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* According with the regular vaccination * Immunization the acellular pertussis diphtheria tetanus vaccine and Measles and rubella combined vaccine

Exclusion criteria

* Disapproval the AEFI information

Design outcomes

Primary

Measure	Time frame	Description
Incidence about AEFI	1.5years	Incidence about AEFI comes from the rate between number of adverse event and the all quantity for immunization about MR and APDT

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026